with afternoon, opportunity. opportunity address share Thank everyone, this I my my as I this for since marks thank great goals first on Since embark want vision you I to to CEO, you and and you, you became joining. Good Ken.
fiscal 'XX, on first, into materially the year move faster we laser-focused growing As we market. than are
for solutions all differentiated delivering outcomes stakeholders. care our and of Second, to greatly improve
Third, and and I offerings my touch these margins this enhancing team, focus by my my to this improving year. business flow. of on the for cash in growing each 'XX. their our Accuray service is will we the year and remarks, finally, and and but dedication I global quarter of want enter start focus customers fiscal thanking as steadfast to serving out this team free
customers since year, year the introductions the in our revenue the Annual with we that rate highest history in growth. more dedicated supply market strong product where patients. growth worldwide months significant revenue, year-over-year with This is outstanding introduction XX growth finished for on to revenue Our teams to deliver We added outstanding unit fourth macro XX% XX% fourth to revenue demonstrated building company orders, In milestones. of reported our and sites our growth. the X% is despite system product new system navigating orders demand CyberKnife estimated that customers XX with challenges product is growth. growing this to-date are results ClearRT and fiscal XXX company's Today, fulfill like $XXX the year-over-year in we Surgery on demand full ClearRT Radixact, quarter was shipped XX well growth their rapid and environment. SBRT the achieved and challenging up and chain Radio see Reflecting incredible representing and quarter, programs as logistics resilience EBITDA ago. new million twice a revenue units for both We support XX% and we our which SX sequentially. as have the imaging radiotherapy and performance for Stereotactic and than adoption we
working. Accuray’s can is market. platform provides year, adjust treatment stops Synchrony system strategy Radixact available introduction image This The time, continuously technology, with of only tumors’ product in movement gating, the the in is of superior as CT and of Our tumor only that strengthened and systems radiation the compared out range. innovation track the Linac location by tumor quality the without use proprietary the delivery we matched when the treatment growth establishing beam conventional real external which to therapy ClearRT industry's is portfolio driven to
the imaging better was conventional New use cost of the Radixact to visualization told significant of also XX%, to from with MedTech Ultra. treat Best ClearRT imaging and awarded Customers we As XXXX speed. treat a patients external average Oncology. of year, performance plan. ClearRT Solution from can have patients Ultra guide greater is departments this introduced the XX VOLO treatment Ultra This provides and to for that The enhancement time enhance that treatment this a VOLO and increased at therapy that VOLO eight result on speed therapy new due XX Breakthrough standard efficiency that to award beam and quality. planning cone an now Customers Technology year operational of day, MRLinac day half have additional the us reported beam planning normally to systems depending an radiation compared per approximately per versatility for reducing
that patient radiation tunnel non-player the a treatment. small therapy the into require beam bore therapy treatments stereotactic thousands of additional be tumor, five reducing growing use can move gained the ultra or while of precision momentum SBRT around capitalizing for design building providers moving and delivers CyberKnife unique the highest from anxiety radiosurgery CyberKnife’s that to angles year, hypofractionated patient, to programs. the less the systems world delivering open rapidly this robotic caused for Additionally, fractions on class other
are patient of the Synchrony standard therapy FY In for five systems, treatment SBRT best with for prostate, eliminates SRS, of due the represent for to like cases it the provide the capability indications system growth growing also use other all and revenue fractions correction demand the to restrictive that less significant Additionally, worldwide. installations tumor lung, required continuous These making XD that breast showed CyberKnife need indications clinical tracking or breathing for approximately key and devices metastases. experience patient. with the radiation ‘XX gold deliver XX% the
only treatments capitalize we fractionation. positioned XX% are to the a market technology representing and will the be expected date demand believe potential on which ultrahypo over is of replacements, to strongly technology ultra However, XX treatments, market Western or aged and approximately Accuray five estimated US to catalyst Europe total years use over alone. the for to in $X drive next billion XXXX older a years hypofractionated
racehorse and for diagnosed to treated the to system their own for his driving treatment we of Gary CyberKnife experiences decisions in reinforced Additionally, patient cancer regarding retired more patients former is name CyberKnife. highest Derby wife's non-invasive Gold, therapy. with precision options, was this five patient fraction on prostate for House for his treatment being trend clinical technology non-surgical decision retired experience as research awareness White Al the reported his who like the system exploring National course incredible XXth positive cancer. Director Also the insert featured saw Admiral We his June USA with Security to Hall, Rear greater after treatment. CyberKnife prostate Accuray CyberKnife Today stories drove being being diligent the due Kentucky its After he treated businessman whose advocated a
are with on have who advocacy educate to options. be by We been working patients technology inspired with treated to patient our groups treatment continue and patients
in region Turning full-year XX% In XX, the EIMEA revenue. won where to orders therapy declined the over growth XX.X% fourth In year we given FY quarter, with our to driven now investments on the performance, goal we seeing Ukraine sub Synchrony latest year COVID radiation while In in XX.X% orders XX.X% demand, are the in year in quarter but two war and will year. X% by greater community. the delivered Europe over tempered geopolitical be increased our infrastructure. new premium we systems Spain are segment. the APAC In Southern a CleaRT the for large return in Americas system the Americas tender available regional Angeles, in fourth lockdown commercial India year high revenue performance of the the we still year by growth due expanding installed year year Radixact patient region, making over order the China increased extended in largely with following over tensions orders public regions. VA region, the LA in to growth and Los we first the In region the at orders consistent access, and
was Synchrony and However, the backlog the ClearRT and In QX, year. region growing Japan Hospital Brisbane headwinds revenue and installed Women's declined flat with over conversion Radixact with strong X% FX at second year also And the prestigious finally, dollar. impacted in XX% Royal system strengthening revenue year year we orders Australia. with over by and the very of US were disproportionately was
side, On partnerships of being competitive Japan up them deliver the turned to reducing fourth of in volume to the the the replacements five installed quarter in orders the positive to we've time with base. solutions really with our competitive conversions past four creating older and the lead continues class year, This with strategic market. of best goal in
treatment online Our of to solutions solution. partnership with planning, RaySearch with OIS strengthen continues development adaptive and
still procedures. a of for optimized imaging doing contouring seeks AI while RaySearch an connectivity provides Our and provide Quentry ClearRT leverage patient CyberKnife their customers and adaptation software brain online table. navigation is partnership plan spine powerful leader a on Element the treatment Brainlab, in treatment of and the and to Accuray’s to algorithms for solution surgical registries
base Our partnership installed neurosurgical of customers leverages to X,XXX Brainlab’s and their over access expertise globally.
non in and breast versatility bunker system for of treated improving with to is Finally, made demonstrated the outcomes the compared technology most solution the Linacs. CRAD less trial expands partnership trial the function physics external co-planar conventional hypofractionated precise of our beam clinical unique abstracts presented heart prostate delivery was hypofractionated were breast abstract B system meeting pain to abstract patients bladder PACE-B for And demonstrated to recognized trigeminal Accuray’s the and after Accuray’s on was cancer at difference CyberKnife highlighting comprehensive to the that of treatment lung Study the multicenter the the radiosurgical in treatments robotic market. clinical negative new the than compared treatment treated ultra showed quality of at and clinical showed years providing patients X.X% with cancer impact improvement sites, breast XX, with with system. This lasted Tomo systems. Synchrony best treated. delivered relief therapy the how single that Radixact FY neuralgia conference. with for in XX as Phase conferences associated the In demonstrating life worldwide hypofractionated enhances XX% CyberKnife the capabilities delivery XXX major the of year, conventional therapy. our use compared to a on in The greater complications patients receiving secondary results XX% the society a study of conventional
‘XX, position Turning us win growth these driven gain working are our strategy and agenda customers for areas fundamentals fiscal new and that year our growth committed strengthen of is to to upon and share. build we to more innovation
pillar ultimate of innovation. objective first for cancer remind building at Accuray, neurological I patients certain our disruptive strategy, of our The or future everyone will diagnosed better diseases. with a
the create expects way We recognized ways to leader patients XX% and we approximately to Accuray of this invest maximum into in a expand provide ensure an back to companies do as talent our the will ‘XX ROI attract into provide our radiation better which innovation envisions therapy MedTech effort and at to innovation R&D the where environment for options revenue care, a effective X% we XX% in to are that into Typical translate an of the for to and We forefront shareholders. committed of industry revenue being true shareholders. R&D, treat back new and long-term invest between are value by FY best help believe forward. we for
programs main the four have development We are the that for company. product top priorities
service our effort which our a more last and we business, has customers this solutions evaluating greater flat in our segments to years and annuity transformation multi-year of embarking become global for for operations. service grow value Additionally, on advance the their efficient offerings all been capture several deliver strengthen by helping and and support an of are our
advanced that For tailored customers system and turnover with seeking shortages are example, needs. training solutions their to specifically provide dealing many more labor
continue profitability departments, have to data system we that can and become powerful insights our geographies. leverage provide also restructured service optimize to organizations we will operational operations closer a and efficiency. will radiation in We of our indirect therapy effectiveness the ensure be tool our and capacity to evaluate that to to target direct and workflow, help customers commercial Further, versus
financial on pillar second margins. focuses The expanding
year fiscal challenges new As the potential we enter to headwinds and ‘XX, new continued emerge. expect macroeconomic we year
We our and plan we look be and supplier solutions, greater optimization, ways rigor laser capture expansion products sustainability. sourcing, efficiency to operating margin will accountability, flexible that our and and optimize increase to focused further to on our with for and supply operate value on and ensuring chain
We to see value the right drive and will for customers, that where margin invest attacking the time at we leakage. we same in expect areas areas our
The third a way work be make is and We operate. simplifying pillar and and durable we decisions business. to make more building the nimbler easier in need
business customers. investment main Approximately As making company to can simplify our areas a into making analytics, investments are The cybersecurity focus work. is the and we more data better faster return protect ultimately our $XX ERP on foundation. make million and effective of and significant provide solidify decision to result, our back we our are fundamentals, investments in so and company and these expected
will is strategies. XXX three XX% pillar just organization and that state-of-the-art A JV three be has The celebrated China, a strong Type market in final China transformational revenue customers, incredible the years that strong to an past people for than be able now year corporate global We the the China. over backlog serve of a Accuray will creation CNMC training manufacturing Our of rate in the facility, conversion. center premium in greater an anniversary win
the largest Type of product million $XXX our sold, systems are segment representing years the in market, the continue to segment with current the China Additionally, of we expected accessing XXXX will portfolio next five potential where to in compete be B market annually. approximately
a market to we developed for B Accuray While 'XX the NMPA COVID be solution growing expect lockdown are jointly and a winning it it our 'XX. and has will in B that Type product, in confident meaningful FY for the delayed are submission FY QX on on-track make of impact Type
premium to the conventional now therapy XX% market, This global currently compete broader beyond Additionally, where segments our to an translation value to Accuray not the over radiation compete financials. of China currently market with market of represents product high the global a systems radiation global do to will we it products. review will allow access the the therapy access, beam hand in Ali performance compete. where incremental I external
